A Detailed Analysis of Clinical Features and Outcomes of Patients with Pyogenic Spondylodiscitis Presenting without Axial Back Pain
暂无分享,去创建一个
[1] L. Nasto,et al. Uncorrect diagnosis of tubercolar spondylodiscitis in aggressive and bone destructive metastasis of melanoma: A case report and literature review , 2020, Orthopedic reviews.
[2] M. Bassetti,et al. Hot Topics on Vertebral Osteomyelitis from the International Society of Antimicrobial Chemotherapy. , 2019, International journal of antimicrobial agents.
[3] G. Maccauro,et al. Multidisciplinary management of pyogenic spondylodiscitis: epidemiological and clinical features, prognostic factors and long-term outcomes in 207 patients , 2018, European Spine Journal.
[4] R. Cauda,et al. New classification for the treatment of pyogenic spondylodiscitis: validation study on a population of 250 patients with a follow-up of 2 years , 2017, European Spine Journal.
[5] F. Oner,et al. Outcome of conservative and surgical treatment of pyogenic spondylodiscitis: a systematic literature review , 2016, European Spine Journal.
[6] E. K. Nickerson,et al. Vertebral osteomyelitis in adults: an update. , 2016, British medical bulletin.
[7] A. Widmer,et al. Executive Summary: 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] A. Widmer,et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] M. Dupon,et al. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial , 2015, The Lancet.
[10] A. Lassen,et al. Increasing incidence of pyogenic spondylodiscitis: a 14-year population-based study. , 2014, The Journal of infection.
[11] C. Fisher,et al. Primary Pyogenic Infection of the Spine in Intravenous Drug Users: A Prospective Observational Study , 2012, Spine.
[12] E. Trecarichi,et al. Epidemiological and clinical features of pyogenic spondylodiscitis. , 2012, European review for medical and pharmacological sciences.
[13] Alpesh A. Patel,et al. Vertebral Osteomyelitis , 2010 .
[14] G. d’Ettorre,et al. A Seven-Year Prospective Study on Spondylodiscitis: Epidemiological and Microbiological Features , 2010, Infection.
[15] E. Mylona,et al. Pyogenic vertebral osteomyelitis: a systematic review of clinical characteristics. , 2009, Seminars in arthritis and rheumatism.
[16] J. Desenclos,et al. Epidemiology of vertebral osteomyelitis (VO) in France: analysis of hospital-discharge data 2002–2003 , 2007, Epidemiology and Infection.
[17] A. Feydy,et al. Comparative study of postoperative and spontaneous pyogenic spondylodiscitis. , 2005, Seminars in arthritis and rheumatism.
[18] A. Freemont,et al. Nerve growth factor expression and innervation of the painful intervertebral disc , 2002, The Journal of pathology.
[19] Kirk A Easley,et al. Vertebral osteomyelitis: long-term outcome for 253 patients from 7 Cleveland-area hospitals. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.